Ramin Hazany, MD
Spinal Cord Injury Medicine · Inglewood, CANPI 1225043185
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Biogen at 27.0% of the total. Reporting peaked in 2022 at $667 and has fallen 91.8% since, to $55 in 2025.
Across 73 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$545
- SK Life Science, Inc.$174
- EMD Serono, Inc.$145
- Abbott$111
- Livanova USA, Inc.$93
- Sanofi$78
- plus $873 from 21 others
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$1,99599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 14 | $545 |
| SK Life Science, Inc. | 7 | $174 |
| EMD Serono, Inc. | 6 | $145 |
| Abbott | 2 | $111 |
| Livanova USA, Inc. | 4 | $93 |
| Sanofi | 3 | $78 |
| Argenx US, Inc. | 3 | $73 |
| Eisai Inc. | 3 | $69 |
| UCB, Inc. | 3 | $67 |
| Amgen | 2 | $67 |
| Tanabe Pharma America, Inc. | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Boston Scientific | 1 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| MDD US Operations, LLC | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| Greenwich Biosciences, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Neurelis, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $27 |
| TG Therapeutics, Inc. | 1 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
How this compares
Too few spinal cord injury medicine providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 48 | $18,135 |
| Oxycodone Hcl | 32 | $245 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $186 |
| Gabapentin | 15 | $20 |
Paid to pharmacies, not to this prescriber.
Other spinal cord injury medicine in Inglewood
- Edward LeroyFresno$12K
- Valerie Chavez-AromOrange$5K
- Christopher BoudakianLos Angeles$4K
- Patricia NanceLong Beach$1K
- Jeremy LouParamount$581
- Muhammad AkbarClovis$192
- Vernon LinLong Beach$189
- Inder PerkashStanford$153
- Shane StoneSacramento$141
- Roy SasakiPalo Alto$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.